Inhibitory action of reveromycin A on TGF-alpha-dependent growth of ovarian carcinoma BG-1 in vitro and in vivo.
The antitumor effect of reveromycin A (RM-A), an inhibitor of EGF-dependent cell proliferation on murine and human tumor cell lines, was examined in vitro and in vivo, RM-A showed little antitumor effect against three murine tumors tested, but showed strong antitumor effect (a minimum treated/control ratio of 36%) against a human ovarian carcinoma BG-1, which is known to be a transforming growth factor alpha (TGF-alpha)-secreting and estrogen receptor-expressing cell line. In BG-1 cells, RM-A inhibited the cell proliferation induced by TGF-alpha at the concentration range 30-300 nM, but did not inhibit the proliferation induced by 17 beta-estradiol (E2).RM-A is a possible new antitumor drug with a novel mechanism of action and may also be a useful tool for the analysis of epidermal growth factor receptor (EGFR)-mediated cell proliferation in tumor cells.
Takahashi
H
H
Institute of Physical and Chemical Research (RIKEN), Saitama, Japan.
Yamashita
Y
Y
Takaoka
H
H
Nakamura
J
J
Yoshihama
M
M
Osada
H
H
D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D002277:Carcinoma / Q000188:drug therapy*; D002455:Cell Division / Q000187:drug effects; D005260:Female; D006131:Growth Inhibitors / Q000494:pharmacology; D006801:Humans; D051379:Mice; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D011714:Pyrans / Q000494:pharmacology*; D013141:Spiro Compounds / Q000494:pharmacology*; D016211:Transforming Growth Factor alpha / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
D000903:Antibiotics, Antineoplastic; D006131:Growth Inhibitors; D011714:Pyrans; D013141:Spiro Compounds; D016211:Transforming Growth Factor alpha; C068098:reveromycin A